Rules-Based Medicine Acquires Intellectual Property Assets of Satoris, Inc.

By Rules-based Medicine Inc., PRNE
Monday, May 16, 2011

Expansion of IP portfolio to support development and commercialization of novel tests for neurodegenerative diseases

AUSTIN, Texas, May 17, 2011 - Rules-Based Medicine (RBM), a global leader in biomarker testing
services, today announced the acquisition of intellectual property assets
from Satoris, Inc. The portfolio is based on extensive research to discover
biomarkers and biomarker panels for clinical and research use in the areas of
Alzheimer's disease, frontal temporal dementia, Parkinson's disease, and
other conditions that affect the central nervous system.

"These assets from Satoris will be an important contributor as we
continue to develop research and diagnostic offerings for neurodegenerative
illnesses which affect millions of individuals and families," said Craig
, President and CEO of Rules-Based Medicine. "Early detection and
intervention will become one of the keys to addressing many of these
illnesses. Rules-Based Medicine is committed to the continued investment into
areas where an earlier and more precise diagnosis can positively impact the
trajectory of these devastating diseases."

Rules-Based Medicine has processed thousands of samples from large
patient cohorts assembled to study Alzheimer's disease. Recently published
scientific articles or release of biomarker results include studies from
Washington University, University of Pennsylvania, the Texas Alzheimer's
Research Consortium (TARC) and the Alzheimer's Disease Neuroimaging
Initiative (ADNI). Using RBM's proprietary testing platform and the
DiscoveryMAP(R) collection of over 250 quantitative immunoassays, researchers
have recognized the importance of proteomic investigation in achieving a more
detailed picture of these complex central nervous system illnesses. RBM will
continue to invest in the development of research and clinical biomarker
panels that can address the needs of drug developers and physicians for early
detection of neurodegenerative disease.

On April 27, 2011, Myriad Genetics of Salt Lake City, a leader in
molecular diagnostics, announced an agreement to acquire Rules-Based
Medicine. The transaction is expected to be complete by May 31, 2011. RBM
headquarters will remain in Austin, TX and will operate as a wholly owned
subsidiary of Myriad Genetics under the name Myriad RBM.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical
researchers, physicians and healthcare providers with reproducible,
quantitative, multiplexed data for hundreds of proteins to advance drug
development and patient care. The Company's proprietary Multi Analyte
Profiling (MAP) technology offers pre-clinical and clinical researchers
broad, cost-effective protein analyses in multiple species from a small
sample volume. MAP technology also supports RBM's drive to develop
diagnostics that aid in the detection of complex diseases and conditions in
areas of unmet medical need such as neuropsychiatry, nephrology, immunology
and cardiology. RBM's initial molecular diagnostic test, VeriPsych(TM) is a
blood-based test that aids in the confirmation of diagnosis of recent-onset
schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also
offers innovative and proprietary ex vivo testing systems such as
TruCulture(TM), the first fully-closed, reproducible whole blood culture
system. More information about RBM is located at

Christopher Martin, Managing Director, Communications, +1-512-275-2623, +1-512-835-8026, Mob, +1-512-627-9058, chris.martin at

will not be displayed